La chaîne d'options affiche les données clés des options sur actions de Indivior à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Indivior..

Indivior (NASDAQ:INDV) Stock, Chaîne d'Options

Indivior

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.

Indivior PLC

INDVR Brands Inc

<p>UBS  analyst Cleveland Rueckert   upgrades Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) from Sell to Neutral and lowers the price target from $62 to $58.</p>


News

Upgrades

Price Target

Analyst Ratings

BALL

UBS Upgrades Ball to Neutral, Lowers Price Target to $58

<p>Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Roblox and provided 12-month price targets. The average target is $58.95, accompanied by a high estimate of $72.00 and a low estimate of $49.00. Observing a 17.66% increase, the current average has risen from the previous average price target of $50.10. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736539254_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Roblox by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Mohammed Khallouf</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$63.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Marok</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Benjamin Black</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Aaron Lee</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Jason Tilchen</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Andrew Marok</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$60.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Nick McKay</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Nick McKay</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Roblox. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Roblox compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Roblox's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Roblox's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RBLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Roblox analyst ratings.</strong></a></p>
<h2>All You Need to Know About Roblox</h2>
<p>Roblox operates an online video game platform with 80 million daily active users that lets young gamers create, develop, and monetize games (or "experiences") for other players. The firm offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning $3.5 billion in bookings in 2023 through in-game purchases and advertising while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers than creating new games or franchises.</p>
<h3>Understanding the Numbers: Roblox's Finances</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Roblox's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>28.84%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> Roblox's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-26.04%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Roblox's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-153.7%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Roblox's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-3.64%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Roblox's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>9.26</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RBLX

A Glimpse Into The Expert Outlook On Roblox Through 21 Analysts

<p>In the last three months, 15 analysts have published ratings on Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along with a high estimate of $48.00 and a low estimate of $33.00. A decline of 9.13% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736539246_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Pinterest's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$39.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Aaron Kessler</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pinterest. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pinterest compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Pinterest's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Pinterest's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PINS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Pinterest analyst ratings.</strong></a></p>
<h2>Delving into Pinterest's Background</h2>
<p>Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.</p>
<h3>A Deep Dive into Pinterest's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Pinterest's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>17.71%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>3.4%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Pinterest's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.0%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Pinterest's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.84%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Pinterest's debt-to-equity ratio is below the industry average at <strong>0.05</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PINS

Analyst Expectations For Pinterest's Future

<p>In the latest quarter, 7 analysts provided ratings for Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Willis Towers Watson, revealing an average target of $363.71, a high estimate of $400.00, and a low estimate of $302.00. This current average reflects an increase of 4.73% from the previous average price target of $347.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736539239_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Willis Towers Watson by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$387.00</td>
<td>$378.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$400.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$380.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$378.00</td>
<td>$359.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$302.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$359.00</td>
<td>$352.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$340.00</td>
<td>$334.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Willis Towers Watson. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Willis Towers Watson compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Willis Towers Watson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Willis Towers Watson's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WTW/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Willis Towers Watson analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Willis Towers Watson</h2>
<p>In January 2016, Towers Watson and Willis Group merged to form Willis Towers Watson, a global advisory, insurance brokerage, and solutions company. The company operates in two business segments: health, wealth, and career (its consulting operations) and risk and brokering (its brokerage operations). It has about 48,000 employees.</p>
<h3>Willis Towers Watson: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Willis Towers Watson showcased positive performance, achieving a revenue growth rate of <strong>5.68%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Willis Towers Watson's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-73.18%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Willis Towers Watson's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-19.91%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Willis Towers Watson's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-5.9%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.8</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


7 Analysts Assess Willis Towers Watson: What You Need To Know

<p>In the preceding three months, 36 analysts have released ratings for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">13</td>
<td align="right">20</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">8</td>
<td align="right">12</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $1077.83, a high estimate of $1300.00, and a low estimate of $900.00. This current average reflects an increase of 12.48% from the previous average price target of $958.26. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736539233_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of ServiceNow's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$1200.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1200.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1210.00</td>
<td>$1045.00</td>
</tr>
<tr>
<td>Robert Majek</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>-</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$1200.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1210.00</td>
<td>$1070.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$1100.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$1300.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1250.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1150.00</td>
<td>$1020.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$1250.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$1150.00</td>
<td>$1075.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1070.00</td>
<td>$980.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1150.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$1071.00</td>
<td>$1068.00</td>
</tr>
<tr>
<td>Peter Weed</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$913.00</td>
<td>$906.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1045.00</td>
<td>$985.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$1025.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$990.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1040.00</td>
<td>$1020.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1050.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$980.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$950.00</td>
<td>$820.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$975.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$1075.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$900.00</td>
<td>$780.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$960.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$1068.00</td>
<td>$915.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1020.00</td>
<td>$825.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$980.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$1000.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$1100.00</td>
<td>$900.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ServiceNow. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ServiceNow compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for ServiceNow's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into ServiceNow's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NOW/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ServiceNow analyst ratings.</strong></a></p>
<h2>Delving into ServiceNow's Background</h2>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<h3>ServiceNow: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> ServiceNow displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>22.25%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>15.45%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> ServiceNow's ROE excels beyond industry benchmarks, reaching <strong>4.81%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> ServiceNow's ROA excels beyond industry benchmarks, reaching <strong>2.36%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.24</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


36 Analysts Assess ServiceNow: What You Need To Know

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>American Express</strong>.</p>
<p>Looking at options history for American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) we detected 29 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 24% of the investors opened trades with bullish expectations and 65% with bearish.</p>
<p>From the overall spotted trades, 15 are puts, for a total amount of $1,209,662 and 14, calls, for a total amount of $832,542.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $145.0 to $330.0 for American Express over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for American Express options trades today is 2067.16 with a total volume of 9,434.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for American Express's big money trades within a strike price range of $145.0 to $330.0 over the last 30 days.</p>
<h3>American Express Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736539228_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.0</td>
<td>$6.8</td>
<td>$7.0</td>
<td>$300.00</td>
<td>$282.1K</td>
<td>1.8K</td>
<td>634</td>
</tr>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.0</td>
<td>$6.9</td>
<td>$7.0</td>
<td>$300.00</td>
<td>$245.7K</td>
<td>1.8K</td>
<td>1.1K</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.45</td>
<td>$4.4</td>
<td>$4.45</td>
<td>$295.00</td>
<td>$156.6K</td>
<td>25</td>
<td>573</td>
</tr>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.0</td>
<td>$6.95</td>
<td>$7.0</td>
<td>$300.00</td>
<td>$114.8K</td>
<td>1.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.5</td>
<td>$3.45</td>
<td>$3.5</td>
<td>$270.00</td>
<td>$99.0K</td>
<td>598</td>
<td>11</td>
</tr>
</tbody>
</table>
</p>
<h3>About American Express</h3>
<p>American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. Since 2018, it has operated in three segments: global consumer services, global commercial services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.</p>
<p>After a thorough review of the options trading surrounding American Express, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is American Express Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,424,232, the AXP's price is down by -2.56%, now at $295.09. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<h3>Professional Analyst Ratings for American Express</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $330.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on American Express with a target price of $340.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on American Express, which currently sits at a price target of $305.<br />
&#x2A; An analyst from Compass Point persists with their Neutral rating on American Express, maintaining a target price of $325.<br />
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $350. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for American Express with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Behind the Scenes of American Express's Latest Options Trends

<p>Financial giants have made a conspicuous bullish move on Accenture. Our analysis of options history for Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 70% of traders were bullish, while 0% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $1,208,500, and 5 were calls, valued at $387,240.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $290.0 to $380.0 for Accenture during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Accenture's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Accenture's whale activity within a strike price range from $290.0 to $380.0 in the last 30 days. </p>
<h3>Accenture 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736539224_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.6</td>
<td>$18.6</td>
<td>$19.35</td>
<td>$350.00</td>
<td>$967.5K</td>
<td align="right">720</td>
<td align="right">503</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.4</td>
<td>$34.2</td>
<td>$34.5</td>
<td>$360.00</td>
<td>$269.1K</td>
<td align="right">214</td>
<td align="right">78</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$31.8</td>
<td>$29.8</td>
<td>$30.8</td>
<td>$350.00</td>
<td>$77.0K</td>
<td align="right">145</td>
<td align="right">25</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.3</td>
<td>$15.7</td>
<td>$16.0</td>
<td>$340.00</td>
<td>$73.6K</td>
<td align="right">263</td>
<td align="right">47</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$8.7</td>
<td>$8.5</td>
<td>$8.5</td>
<td>$325.00</td>
<td>$59.5K</td>
<td align="right">175</td>
<td align="right">70</td>
</tr>
</tbody>
</table>
</p>
<h3>About Accenture</h3>
<p>Accenture is a leading global IT services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.</p>
<p>After a thorough review of the options trading surrounding Accenture, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Accenture's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,257,354, the price of ACN is down by -2.33%, reaching $349.39.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 69 days from now.</li>
</ul>
<h3>Expert Opinions on Accenture</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $425.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Accenture with a target price of $429.<br />
&#x2A; An analyst from UBS persists with their Buy rating on Accenture, maintaining a target price of $455.<br />
&#x2A; An analyst from BMO Capital persists with their Market Perform rating on Accenture, maintaining a target price of $425.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Accenture, maintaining a target price of $396.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Accenture, targeting a price of $422. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Accenture with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Accenture's Options Frenzy: What You Need to Know

<p>Throughout the last three months, 13 analysts have evaluated VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.38, a high estimate of $27.00, and a low estimate of $15.00. Surpassing the previous average price target of $19.27, the current average has increased by 10.95%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736539223_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of VF by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Staszak</td>
<td>Argus Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$19.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to VF. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of VF compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of VF's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into VF's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VFC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on VF analyst ratings.</strong></a></p>
<h2>Get to Know VF Better</h2>
<p>VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.</p>
<h3>VF: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, VF faced challenges, resulting in a decline of approximately <strong>-5.55%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> VF's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>1.89%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>3.73%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.44%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> VF's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>5.25</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


13 Analysts Have This To Say About VF

<p>Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BMY usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Bristol-Myers Squibb. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 30% leaning bullish and 70% bearish. Among these notable options, 2 are puts, totaling $167,800, and 8 are calls, amounting to $640,598.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $43.0 to $60.0 for Bristol-Myers Squibb over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Bristol-Myers Squibb options trades today is 3581.67 with a total volume of 2,064.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Bristol-Myers Squibb's big money trades within a strike price range of $43.0 to $60.0 over the last 30 days.</p>
<h3>Bristol-Myers Squibb Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736539218_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.55</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$55.00</td>
<td>$268.8K</td>
<td>10.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.0</td>
<td>$5.9</td>
<td>$6.0</td>
<td>$60.00</td>
<td>$106.8K</td>
<td>1.5K</td>
<td>183</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.6</td>
<td>$13.65</td>
<td>$14.32</td>
<td>$43.00</td>
<td>$71.6K</td>
<td>6.0K</td>
<td>50</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$55.00</td>
<td>$70.7K</td>
<td>10.9K</td>
<td>247</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.5</td>
<td>$7.45</td>
<td>$7.45</td>
<td>$52.50</td>
<td>$65.5K</td>
<td>1.5K</td>
<td>89</td>
</tr>
</tbody>
</table>
</p>
<h3>About Bristol-Myers Squibb</h3>
<p>Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.</p>
<p>In light of the recent options history for Bristol-Myers Squibb, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Bristol-Myers Squibb's Current Market Status</h3>
<ul>
<li>Trading volume stands at 5,399,329, with BMY's price down by -1.0%, positioned at $56.24.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>What Analysts Are Saying About Bristol-Myers Squibb</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $67.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Jefferies has elevated its stance to Buy, setting a new price target at $70.<br />
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Bristol-Myers Squibb, which currently sits at a price target of $65. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bristol-Myers Squibb options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?

<p>During the last three months, 22 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">15</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1038.68, with a high estimate of $1260.00 and a low estimate of $165.00. Observing a downward trend, the current average is 12.2% lower than the prior average price target of $1183.06. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736539213_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$900.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1004.00</td>
<td>$1126.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1070.00</td>
<td>$1110.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Hold</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$565.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1150.00</td>
<td>-</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$895.00</td>
<td>-</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1184.00</td>
<td>$1235.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1215.00</td>
<td>$1260.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1065.00</td>
<td>$1080.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1195.00</td>
<td>$1242.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1190.00</td>
<td>$1300.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1126.00</td>
<td>$1137.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1260.00</td>
<td>$1260.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1175.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1150.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1015.00</td>
<td>$1015.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1080.00</td>
<td>$1220.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1050.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1260.00</td>
<td>$1260.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1137.00</td>
<td>$1200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Regeneron Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Regeneron Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Regeneron Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/REGN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Regeneron Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Get to Know Regeneron Pharmaceuticals Better</h2>
<p>Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<h3>Regeneron Pharmaceuticals: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Regeneron Pharmaceuticals displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.65%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Regeneron Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>36.03%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.66%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>3.65%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average at <strong>0.09</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


REGN

Forecasting The Future: 22 Analyst Projections For Regeneron Pharmaceuticals

<p>UBS  analyst Joshua Spector   downgrades Pactiv Evergreen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTVE#NASDAQ">PTVE</a>) from Buy to Neutral and raises the price target from $16 to $18.</p>


Downgrades

PTVE

UBS Downgrades Pactiv Evergreen to Neutral, Raises Price Target to $18

<p>The <strong>iShares Semiconductor ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) finds itself at a crossroads. JPMorgan&#8217;s latest technical update reveals that the Philadelphia Semiconductor Index, a benchmark for the iShares Semiconductor ETF, has largely&nbsp;been propelled&nbsp;to&nbsp;the upper limit of&nbsp;a multimonth trading range by a rally in AI-related stocks. </p>
<p>Yet the index now faces stiff resistance near 5,400, raising questions about its ability to sustain a long-term rally without support from the more cyclical analog <a href="https://www.benzinga.com/topic/semiconductors">semiconductor </a>group.</p>
<p>AI has been transforming industries and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42921523/nvidias-lead-expands-analyst-says-ai-demand-remains-very-strong">driving demand</a> for semiconductors. Leading chipmakers like <strong>Nvidia </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and <strong>Broadcom </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) have led the rally, riding the AI wave. Nvidia&#8217;s advanced Blackwell GPUs and Broadcom's custom AI accelerators enjoy solid market interest. <br /><br />JPMorgan warns the heavy reliance on AI names could be risky, as the analog semiconductor group, closely linked with global manufacturing cycles, dawdles.</p>
<p>JPMorgan said the analog segment is not performing up to par and this is consistent with with the PMI level globally being around 50, indicating a certain level of pessimism. SOXX would need participation from this segment to break out of its trading range and sustain a broader rally.</p>
<p>&#8220;We also highlight just how correlated the analog group is to the global manufacturing cycle, with the current pricing roughly in line with a 50 global manufacturing PMI reading. That coincides with the US exceptionalism theme that seems priced across markets in other asset classes,&#8221; JPMorgan analysts said in a note. </p>
<h3 class="wp-block-heading">Why SOXX Still Holds Promise</h3>
<p>Despite these concerns, SOXX offers a strong value proposition for investors looking for exposure to the semiconductor industry&#8217;s growth. The ETF, which focuses solely on chip companies, is expected to capitalize on the AI spending boom. With Nvidia, Broadcom and <strong>Advanced Micro Devices</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) accounting for significant portions of its portfolio, SOXX bets heavily on the sector's leaders.</p>
<p><strong>Microsoft </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), <strong>Amazon </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), <strong>Alphabet </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and <strong>Meta Platforms</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) alone are projected to spend $300 billion on AI infrastructure by 2025, according to a November report by Business Insider citing Morgan Stanley. This influx of investment bodes well for the ETF, which has holdings in nearly every key hardware stock involved in the AI revolution. With a 7.84% weighting in the ETF, Nvidia will expose investors to its industry leading advancements, whereas diversification within the AI hardware universe will come from Broadcom (with 10.94% weightage) and AMD (6.87%).</p>
<h3 class="wp-block-heading">Watchful Optimism</h3>
<p>JPMorgan's analysis brings both opportunities and risks for iShares Semiconductor ETF to the spotlight. For instance, a 2-point improvement in global manufacturing PMI could open up a 20% upside for the analog semiconductor group, as analyzed by JP Morgan. This can potentially improve the overall performance of iShares Semiconductor ETF. Conversely, the dependence of the ETF on AI-driven growth makes it sensitive to setbacks of the highly fragmented broader semiconductor market.</p>
<p><strong>See Next: </strong></p>
<ul>
<li><a href="https://www.benzinga.com/25/01/42922934/oil-stocks-rally-on-anticipation-of-stricter-russian-sanctions-heres-how-etfs-are-reacting"><strong>Oil Stocks Rally On Anticipation Of Stricter Russian Sanctions: Here&#8217;s How ETFs Are Reacting</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em>.</p>


Analyst Color

Equities

Sector ETFs

Tech

ETFs

AMZN

AVGO

GOOGL

MSFT

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Semiconductor ETF Faces Key Resistance In AI-Driven Surge: Analyst

<p><strong>Palantir Technologies Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) joined the prestigious <a href="https://www.benzinga.com/topic/nasdaq-100"><strong>Nasdaq-100 index</strong></a> on Dec. 23, a milestone often seen as a vote of confidence for companies with promising growth trajectories.</p>
<p>Yet, rather than boosting investor sentiment, the stock has since tumbled over 15%, vastly underperforming broader market benchmarks. </p>
<p>For comparison, the <strong>SPDR S&amp;P 500 ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) slipped just 0.87%, while the tech-heavy <strong>Invesco QQQ Trust, Series 1 </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell a modest 1.45% during the same period.</p>
<h1 class="wp-block-heading">High Expectations, Harsh Reality</h1>
<p>Inclusion in the Nasdaq-100 is usually accompanied by a wave of enthusiasm. However, Palantir&#8217;s slide underscores mounting challenges facing high-growth tech firms. </p>
<p>Market sentiment has turned cautious as investors question the sustainability of lofty valuations amid economic uncertainty and rising interest rates. Despite expanding its footprint in commercial sectors and securing high-profile contracts, Palantir faces skepticism over its cost structure and pathway to profitability. </p>
<p>Palantir's heavy focus on government contracts and its complex business model have become key points of scrutiny. </p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/equities/25/01/42891906/palantir-cto-shyam-sankar-challenges-automations-potential-as-selling-pressure-mounts-what-have-we-been-doing-for-20-years">Palantir CTO Shyam Sankar Challenges Automation&#8217;s Potential As Selling Pressure Mounts: &#8216;What Have We Been Doing For 20 Years?&#8217;</a></strong></p>
<h1 class="wp-block-heading"><strong>Palantir Stock: Mixed Signals From Moving Averages</strong></h1>
<p><figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10134353/Screenshot-2025-01-11-at-12.13.39-AM.png" alt="" class="wp-image-728797" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10134353/Screenshot-2025-01-11-at-12.13.39-AM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10134353/Screenshot-2025-01-11-at-12.13.39-AM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure></p>
<p><em><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a></em></p>
<p>At $67.40, PLTR stock shows divergence across key moving averages:</p>
<ul>
<li>The eight-day SMA (simple moving average) at $73.68 and 20-day SMA at $75.60 both indicate a bearish outlook, reflecting downward short-term momentum.</li>
<li>Meanwhile, the 50-day SMA at $66.53 suggests a bullish signal, highlighting possible mid-term recovery potential.</li>
<li>The 200-day SMA at $38.10 reinforces a bullish stance, underscoring investor optimism over the long term.</li>
</ul>
<h1 class="wp-block-heading"><strong>MACD, RSI Indicators Suggest Tentative Strength</strong></h1>
<p>The MACD (moving average convergence/divergence) indicator reads 1.16, signaling bullish momentum as upward pressure builds. </p>
<p>The Relative Strength Index (RSI) at 41.97 remains in the neutral territory, implying PLTR stock is neither overbought nor oversold, indicating a balanced market sentiment.</p>
<h1 class="wp-block-heading"><strong>Balancing Bearish Signals With Recovery Potential</strong></h1>
<p>Despite short-term bearish indicators, Palantir&#8217;s ability to maintain key support levels signals potential for recovery. The contrast between short-term pressure and long-term bullish trends highlights the importance of closely monitoring price movements.</p>
<p>With market dynamics shifting, investors should brace for continued volatility, keeping a watchful eye on technical developments and broader economic conditions.</p>
<p>As tech stocks face heightened scrutiny, Palantir's journey on the Nasdaq-100 will be a crucial gauge of whether the company can realign investor sentiment and stabilize its market trajectory.</p>
<p><strong>Read Also: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/global/25/01/42910173/palantir-co-founder-joe-lonsdale-sets-realistic-expectations-for-elon-musks-doge-initiative-next-trillion-will-be-a-lot-harder">Palantir Co-Founder Joe Lonsdale Sets Realistic Expectations For Elon Musk&#8217;s DOGE Initiative: &#8216;Next Trillion Will Be A Lot Harder&#8217;</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Long Ideas

Technicals

Trading Ideas

PLTR

Palantir's Nasdaq-100 Hype Fades As Stock Sinks 15% Post-Inclusion

<p>UBS  analyst Joshua Spector   upgrades Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Neutral to Buy and maintains the price target from $144 to $144.</p>


UBS Upgrades Westlake to Buy, Maintains Price Target to $144

<p>UBS  analyst Joshua Spector   maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and lowers the price target from $74 to $73.</p>


CTVA

UBS Maintains Buy on Corteva, Lowers Price Target to $73

<p>On Thursday, <strong>Truist </strong>initiated coverage on <strong>BioNTech SE</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), a famed COVID-19 vaccine maker, in collaboration with<strong> Pfizer Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).</p>
<p>BioNTech is transitioning from a COVID-focused narrative to a story centered on oncology drug development <a target="_blank" href="https://www.benzinga.com/24/12/42370209/why-is-biontech-stock-trading-higher-on-friday" rel="noreferrer noopener">and upcoming catalysts.</a></p>
<p>The analyst, Asthika Goonewardene, writes that BNT327 is at the forefront, a promising drug in an innovative class that could challenge and potentially surpass the PD-1 category, which generated over $42 billion in 2023.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41866389/biontech-earns-upgrade-from-goldman-sachs-as-investment-thesis-shifts-toward-cancer-potential" rel="noreferrer noopener">BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential</a></strong></p>
<p>While<strong> Summit Therapeutics Inc&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) ivonescimab may have a head start in certain areas, BioNTech&#8217;s stronger financial position and pipeline of complementary products give it a strategic edge. With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds.</p>
<p>In November, BioNTech agreed to acquire&nbsp;<strong>Biotheus</strong>, a clinical-stage biotechnology company focused on discovering and developing antibodies for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41949384/biontech-boosts-oncology-strategy-with-800-million-china-based-biotheus-acquisition" rel="noreferrer noopener">oncological or inflammatory diseases</a>.</p>
<p>With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.</p>
<p>Truist initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/BNTX/analyst-ratings" rel="noreferrer noopener">price target of $172</a>.</p>
<p>BioNTech&#8217;s oncology pipeline was previously seen as limited in value outside BNT316. However, with BNT327 gaining traction and new data expected in 2025 to clarify the potential of other pipeline assets, there is room for greater investor appreciation of the company&#8217;s oncology portfolio, Truist analyst adds.</p>
<p>Goonewardene also writes that <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">COVID-19 remains a significant factor</a> in BioNTech&#8217;s stock performance and that COVID-related developments will continue to influence BioNTech&#8217;s stock.</p>
<p>The analyst highlights that BNT327 could be the first drug approved in the U.S. and Europe for key conditions like triple-negative breast cancer and small cell lung cancer, potentially generating around $2 billion at peak sales.</p>
<p>For non-small cell lung cancer, Truist expects BNT327 to follow shortly, contributing over $4 billion in revenue.</p>
<p><strong>Price Action:</strong> BNTX stock is up 0.55% at $122.82 at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42918973/wayfair-waves-goodbye-to-germany-heres-why" target="_blank" rel="noreferrer noopener">Wayfair Waves Goodbye To Germany &#8211; Here&#8217;s Why</a></strong></li>
</ul>
<p><em>Image via Shutterstock.</em></p>


Biotech

Large Cap

Initiation

General

BNTX

SMMT

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

WIIM

SPGI

S&P Global shares are trading lower after Wells Fargo cut its price target on the stock from $620 to $617.

<p>UBS  analyst Joshua Spector   maintains Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Neutral and lowers the price target from $235 to $207.</p>


UBS Maintains Neutral on Avery Dennison, Lowers Price Target to $207

<p>UBS  analyst Curt Woodworth   maintains Ardagh Metal Packaging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBP#NYSE">AMBP</a>) with a Neutral and lowers the price target from $4.25 to $2.75.</p>


AMBP

UBS Maintains Neutral on Ardagh Metal Packaging, Lowers Price Target to $2.75

STNG

TALO

TRGP

VTLE

Shares of oil, gas and tanker companies are trading higher following reports suggesting the US is preparing sanctions against Russian oil and gas.

In a report released today, James Vane from Jefferies reiterated a Buy rating on Indivior (INDV – Research Report), with a price target of p1,800.0...

Jefferies Sticks to Its Buy Rating for Indivior (INDV)

Indivior CFO steps down from board after discussions with Oaktree Capital

Indivior ( ($GB:INDV) ) has provided an announcement. Indivior PLC announced that Robert Schriesheim, a Non-Executive Director, acquired 21,400 Ord...

Indivior Director Acquires Significant Shareholding

Indivior ( ($GB:INDV) ) just unveiled an update. Indivior PLC announced the repurchase and cancellation of 209,246 of its ordinary shares as part o...

Indivior Announces Share Repurchase and Cancellation

An update from Indivior ( ($GB:INDV) ) is now available. Indivior PLC announced the repurchase and cancellation of 209,246 of its ordinary shares t...

Indivior Executes Share Repurchase Under $100 Million Program

Indivior ( ($GB:INDV) ) just unveiled an update. Indivior PLC announced the purchase and cancellation of 92,950 of its ordinary shares as part of i...

Indivior Advances Shareholder Value with Share Repurchase

The latest announcement is out from Indivior ( ($GB:INDV) ). Indivior PLC has been notified of a change in major holdings involving Two Seas Capita...

Indivior PLC Experiences Change in Major Shareholdings

Indivior ( ($GB:INDV) ) has provided an announcement. Indivior PLC has announced its total voting rights and capital, stating that as of January 1,...

Indivior Announces Total Voting Rights and Capital Update

Indivior ( ($GB:INDV) ) has issued an update. Indivior PLC, a UK-based company, announced that Madison Avenue Partners LP, a New York-based investm...

Madison Avenue Partners Increases Stake in Indivior PLC

Indivior ( ($GB:INDV) ) just unveiled an announcement. Indivior has announced its transition to a US primary listing by providing historical financ...

Indivior Transitions to US GAAP for Enhanced Market Positioning

COLL

INDV

Small Cap

Press Releases

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)

Legal

Investors who lost money on Indivior PLC(INDV) should contact Levi & Korsinsky about pending Class Action - INDV

INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Indivior PLC(INDV) Shareholders

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Earnings

Indivior Announces Q3 2024 Financial Results

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Liquidia

Merck & Co

Nuvation Bio

Novo Nordisk

Novartis

Ocular Therapeutix

Organon

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pacira BioSciences

Pfizer

Pliant Therapeutics

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Septerna

Sanofi

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Indivior

Indivior (INDV) Options

Indivior (NASDAQ:INDV) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL